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SUMMARY
Background: Intragastric acid suppression is the most
direct measure of the pharmacodynamic efficacy of
proton pump inhibitors, which are the most effective
drugs for acid-related diseases.
Aim: To compare the effectiveness of once and twice
daily dosing of lansoprazole and esomeprazole in con-
trolling intragastric acidity (target gastric pH > 4.0)
over a 24-hour period.
Methods: In an open-label, two-way crossover study, 45
Helicobacter pylori-negative patients with gastro-oeso-
phageal reflux disease were randomized to receive one
of two regimens: 30 mg lansoprazole or esomeprazole
40 mg once daily. Intragastric pH was assessed by 24-
hour pH monitoring on day 5 of each regimen. Dosing
was increased to twice daily and pH was reassessed on
day 10. Following a 14-day washout, patients were
crossed over to the other medication and the dosage
regimens and pH assessments were repeated.
Results: Data were analysed from 35 patients who
completed all scheduled assessments and had 24-hour
monitoring for each end-point. Mean time pH > 4.0 and
mean 24-hour pH were highest for esomeprazole 40 mg
twice daily, followed by lansoprazole 30 mg twice daily,
esomeprazole 40 mg once daily and lansoprazole 30 mg
once daily. Esomeprazole 40 mg twice daily provided
superior control of intragastric pH compared with either
once or twice daily dosing of lansoprazole and once
daily dosing of esomeprazole (P < 0.01). Esomeprazole
40 mg once daily was comparable with lansoprazole
30 mg twice daily and both were superior to lansopra-
zole 30 mg once daily (P < 0.01).
Conclusions: Response to acid suppression treatment
depends on the treatment selected. Esomeprazole 40 mg
twice daily provided better control of intragastric pH
than all other regimens evaluated. Esomeprazole 40 mg
daily, however, was comparable with lansoprazole
30 mg twice daily and superior to lansoprazole 30 mg
once daily.
INTRODUCTION
Gastro-oesophageal reflux disease (GERD) is a common
disorder characterized by heartburn symptoms, acid
regurgitation or the presence of oesophageal lesions.
The development of these symptoms and mucosal injury
in patients with GERD depends on intragastric pH.1
Proton pump inhibitors (PPIs) are the most effective
drugs for acid-related diseases, including GERD, with
proven superiority to histamine H2-receptor antago-
nists.2 Proton pump inhibitors suppress gastric acid
secretion through the inhibition of H+/K+ adenosine
triphosphatase in gastric parietal cells.3 Intragastric
acid suppression, measured as the number of hours in a
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24-hour period that intragastric pH is maintained above
4.0, is used to compare the effects of PPIs4–6 and is
correlated with mucosal healing rates in erosive
oesophagitis.7
Esomeprazole is the S-isomer of omeprazole and the
first PPI developed as a single isomer. Esomeprazole has
an enhanced pharmacodynamic and pharmacokinetic
profile resulting in more effective and longer-lasting
inhibition of gastric acid secretion over the 24-hour
dosing period8–10 and is more effective at healing and
resolution of heartburn than the racemic omepra-
zole.11–13 Intragastric acid is more effectively controlled
with the standard dose of esomeprazole (40 mg once
daily) than standard doses of all other PPIs, as measured
by the percentage of time pH > 4.0 and mean 24-hour
pH.14–17 Furthermore, esomeprazole provides complete
heartburn relief in the majority of patients with GERD.18
Compared with lansoprazole, esomeprazole has been
shown to be more effective in resolving heartburn with
faster sustained relief and in healing erosive oesopha-
gitis.19, 20
The primary objective of this study was to compare the
effects of once and twice daily dosing of esomeprazole
40 mg and lansoprazole 30 mg on intragastric pH over a
24-hour period in patients with GERD symptoms. This
study uses a novel crossover design to evaluate the effects
of once and twice daily dosing of two different PPIs.
PATIENTS AND METHODS
Patients
Men and women aged between 18 and 75 years who
were negative for Helicobacter pylori (breath test or
biopsy within 1 month of study entry) and had a history
of heartburn symptoms averaging at least 2 days/
month during the last 2 months before screening or a
history of GERD documented by endoscopy, pH study or
prior response to PPI therapy were eligible for the study.
Women were required to not be pregnant or lactating,
and those of child-bearing potential had to be surgically
sterile or be using an acceptable method of birth control.
Patients were excluded if they had a history of
gastrointestinal disease, gastrointestinal surgery or
other conditions that may affect absorption or pharma-
cokinetics of the study drug. In addition, patients were
excluded if they required chronic aspirin >325 mg/day,
non-steroidal anti-inflammatory drugs or medication
that depends on the presence of gastric acid for optimal
absorption, such as ketoconazole, iron salts, digoxin or
ampicillin esters. Patients treated with prescription-
strength H2-receptor antagonists, prokinetic medica-
tions or medications that could alter the pharmacoki-
netics of PPIs within 2 weeks before the first dose of
study drug were excluded.
Patients on pre-existing PPI therapy were required to
discontinue treatment at least 10 days before random-
ization. Those who could not stop their GERD therapy
were not permitted to enter the study. Patients with a
history of ‡3 heartburn episodes per week before study
entry were required to have an oesophagogastroduo-
denoscopy before randomization to rule out oesopha-
geal erosions, ulcers, oesophageal or gastric neoplasms,
Barrett’s oesophagus or other upper endoscopic pathol-
ogy. Patients with significant gastrointestinal pathology
were not enrolled.
Patients could not participate in the study if they had a
significant clinical illness during the study or within
2 weeks before the first dose of study drug or had a
history of a clinically significant medical condition
whose treatment may be adversely impacted by parti-
cipation. Patients who received an investigational drug
or used an experimental device within 30 days before
screening or donated blood within 8 weeks before
screening also were ineligible to participate. Addition-
ally, patients were required to have no abnormal
laboratory values that were clinically significant and
be within 25% of ideal body weight for their height and
frame. Patients who smoked >10 cigarettes per day or
used the equivalent nicotine-containing product, con-
sumed more than four cups of coffee or caffeine-
containing beverages per day, consumed alcohol within
1 week before or during the study, had a history of drug
or alcohol dependence or current abuse, had a history of
intolerance to esomeprazole or any other approved PPI
or had a history of multiple drug allergies or drug-
associated adverse events were excluded.
Study design
A randomized, open-label, single-centre, four-treatment,
two-way crossover comparative study assessed the effect
of two doses each of esomeprazole and lansoprazole on
intragastric pH. Patients were randomized by a compu-
ter-generated randomization schedule to receive either
lansoprazole 30 mg or esomeprazole 40 mg once daily
(30 minutes before a standardized breakfast) for 5
consecutive days (Figure 1). Dosing regimens were then
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increased to twice daily (30 minutes before breakfast
and dinner) for an additional 5 consecutive days. The
first dose of the first day of each treatment arm was
administered in the study clinic. All subsequent doses
were taken by the patients at home. Patients were
instructed on a standardized diet and were asked to be
consistent throughout the study. Following a 10- to
14-day washout, patients were crossed over to the other
treatment. An ambulatory 24-hour intragastric pH
recording was done on day 5 to day 6 during each
treatment period. The pH probe (Medtronics, Minne-
apolis, MN, USA) was placed 10 cm below the distal
border of the manometrically defined lower oesophageal
sphincter. After the 24-hour, pH profile was obtained
for treatment periods 1 and 3, the pH probe was
removed (day 6) and subsequently the first dose of the
appropriate study medication was administered to begin
the next treatment period. Rescue medication with
Gelusil [Warner Lambert Consumer Healthcare (Parke
Davis), Morris Plains, NJ, USA] was permitted (maxi-
mum of six tablets/day) except after midnight on day 4
and during pH monitoring on days 5 and 6. Patients
were ambulatory and outpatients during the 24-hour
intragastric pH monitoring. A minimum of 22 hours
was chosen as a threshold for acceptable data to be
included for analysis. The hours were then extrapolated
proportionately to allow for standardized comparisons
between each of the treatment arms, based on 24 hours
of monitoring.
Statistical analysis
The primary end-point was the percentage of time
intragastric pH was >4.0 on day 5 and was analysed
using one-way repeated analyses of variance (anova)
and Duncan’s Multiple Range tests. Six paired compar-
isons of hours with pH > 4 were made among the four
treatments. Assuming a 10% difference in the percent-
age of time intragastric pH > 4.0 between esomeprazole
40 mg b.d. and lansoprazole 30 mg b.d., 36 patients
were needed to provide 90% power to detect this
difference at a significance level of 0.05.
Data for each of the four treatments were analysed with
the statistical software package SPSS. Each patient
received each of the four treatments; therefore, a
randomized complete block design was assumed with
each patient serving as a block. To determine which
treatment differed from the others, the Sidak method of
multiple comparisonswas invoked to protect against false
significances (i.e. Type 1 errors) using an error rate of
0.05.
Ethics
The study was conducted in accordance with the
Declaration of Helsinki, US Food and Drug Administra-
tion guidance, Good Clinical Practice regulations and
Guidelines for the Monitoring of Clinical Investigations.
In addition, the study was approved by the Institutional
Review Board and each patient provided written
informed consent before enrollment.
RESULTS
Study population
Forty-five patients were randomized into the study
(Figure 1). Demographic characteristics of the 35
patients who completed all scheduled assessments and
24-hour monitoring for each treatment are summarized
in Table 1.
Time pH > 4.0
When treated with esomeprazole 40 mg b.d., patients
had a higher average response (number of hours with
Esomeprazole 40 mg 
once daily x 5 days
Lansoprazole 30 mg 
once daily x 5 days
Esomeprazole 40 mg 
twice daily x 5 days
Lansoprazole 30 mg
twice daily x 5 days
Lansoprazole 30 mg 
once daily x 5 days
Esomeprazole 40 mg 
once daily x 5 days
Lansoprazole 30 mg 
twice daily x 5 days
Esomeprazole 40 mg
twice daily x 5 days
24-hour pH profile conducted on day 5 of each treatment




Figure 1. Study design.
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pH > 4) than with each of the other treatments; the
average response with esomeprazole 40 mg daily was
higher than with lansoprazole 30 mg daily; and the
average response with lansoprazole 30 mg b.d. was
higher than with lansoprazole 30 mg once daily
(Figure 2).
Mean 24-hour pH
The mean 24-hour pH was significantly higher during
treatment with esomeprazole 40 mg once or b.d.
when compared with lansoprazole 30 mg once daily
(P < 0.01 and P < 0.001, respectively; Figure 3).
Mean 24-hour pH was significantly higher (P <
0.01) when patients were treated with esomeprazole
40 mg b.d. than when they were treated with
esomeprazole 40 mg once daily; esomeprazole once
daily was not significantly different from lansoprazole
30 mg b.d. The mean pH achieved with lansoprazole
30 mg b.d. also was significantly higher than that
achieved with lansoprazole 30 mg once daily
(P < 0.001).
DISCUSSION
The results of this study demonstrate that greater
intragastric acid suppression occurs with esomeprazole
40 mg b.d. compared with once daily dosing and is
superior to that of lansoprazole 30 mg whether
administered once or twice daily. Esomeprazole
40 mg administered once daily results in a greater
number of hours with pH > 4 than lansoprazole
30 mg administered once daily and a similar number
of hours with pH > 4 compared with lansoprazole
30 mg b.d.
Previous studies have demonstrated that intragastric
acid is more effectively controlled with esomeprazole
than rabeprazole, omeprazole, lansoprazole and pan-
toprazole, as measured by the percentage of time
pH > 4.0 and mean 24-hour pH.14–17 In a five-way
crossover study, standard-dose esomeprazole also was
shown to provide a greater mean number of hours in a
24-hour period with pH above prespecified thresholds
(between 2.0 and 6.0) than standard doses of rabep-
razole, omeprazole, lansoprazole and pantoprazole.17
These results are consistent with those of previous
studies comparing standard and escalated doses of
esomeprazole, either alone or in comparison with other
PPIs. Recently, a randomized, three-way, dose-ranging
crossover study of healthy subjects showed that eso-
meprazole 40 mg b.d. provides significantly greater acid
suppression (hours with pH > 4) than esomeprazole
20 mg b.d. or 40 mg once daily [19.2 hours (80.1% of
24-hour period; 95% confidence interval (CI) 74.5–
85.7%); 14.2 hours (59.2% of 24-hour period; 95% CI
53.7–64.7); and 17.5 hours (73% of 24-hour period;
Table 1. Demographic characteristics of patients included in
analyses
Characteristic (n ¼ 35)
Women
n (%) 22 (63)
Mean age, year (range) 46 (29–71)
White/Black/Asian, n 17/4/1
Men
n (%) 13 (37)









































Figure 2. Mean number of hours in a 24-hour period (95% CI)



































Figure 3. Mean 24-hour intragastric pH on day 5 (n ¼ 35).
*P < 0.001 vs. lansoprazole 30 mg once daily. P < 0.01 vs.
esomeprazole 40 mg once daily. P < 0.01 vs. lansoprazole
30 mg once daily.
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95% CI 67.4–78.5), respectively].21 In a study of
patients with Barrett’s oesophagus who received three
different dosing regimens of esomeprazole (20 mg t.d.s.,
40 mg b.d. and 40 mg t.d.s.), all three regimens were
shown to provide high levels of intragastric acid
suppression.22 In addition, the number of hours or
mean percentage of time in a 24-hour period with
intragastric pH > 4.0 increased with increasing eso-
meprazole dosage, and the 40-mg 3-times-daily regimen
provided statistically superior gastric acid suppression
compared with the other two regimens (P < 0.01).22 In
healthy subjects, standard doses of esomeprazole
(40 mg once daily) provided longer and more effective
intragastric acid control than both standard and double
doses of lansoprazole (30 and 60 mg once daily,
respectively).23 Furthermore, in a comparison of twice
daily dosing of esomeprazole 40 mg and pantoprazole
40 mg in healthy subjects, esomeprazole was signifi-
cantly more effective at controlling intragastric pH.24
Suboptimal symptomatic response to PPI therapy may
lead the physician to double the PPI dose rather than
switch the medications. Besides the superiority of
intragastric acid control with esomeprazole treatment
shown from the results of previous studies, single-dose
esomeprazole also has been shown to control heartburn
symptoms as well as double-dose lansoprazole admin-
istered once daily in patients with GERD symptoms
refractory to lansoprazole 30 mg once daily.25 Further-
more, switching from a twice daily PPI to once daily
esomeprazole is clinically successful and cost-saving.26
This treatment strategy may be an effective way to
manage GERD in patients requiring greater than a
single daily dose of PPI to achieve an acceptable level of
acid suppression.
Results of this study suggest that greater control of
acid secretion depends on the medication selected as
well as the dose selected. By extrapolation to clinical
practice, these data also suggest that doubling the
dosage of lansoprazole may not be a cost-effective
strategy to increase intragastric acid suppression given
the comparable pH effect achieved with single-dose
esomeprazole. Outcome studies to validate this hypo-
thesis are presently under way.
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